Xilio Therapeutics (XLO) Payables (2020 - 2026)

Xilio Therapeutics has disclosed Payables across 7 years of filings, most recently posting $2.3 million for Q2 2026.

• In Q2 2026, Payables fell 43.5% year-over-year to $2.3 million; the TTM figure through Jun 2026 stood at $2.3 million (down 43.5% YoY), while the FY2025 annual figure was $3.2 million, up 23.08% from the prior year.
• Payables came in at $2.3 million for Q2 2026 at Xilio Therapeutics, up from $1.1 million in the prior quarter.
• In the past five years, Payables ranged from a high of $9.8 million in Q4 2022 to a low of $746000.0 in Q1 2024.
• Average Payables over 5 years is $4.1 million, with a median of $3.6 million recorded in 2022.
• Year-over-year, Payables slumped 91.41% in 2024 and surged 224.13% in 2025.
• Over 5 years, Payables stood at $9.8 million in 2022, then slumped by 55.42% to $4.4 million in 2023, then plunged by 41.03% to $2.6 million in 2024, then rose by 23.08% to $3.2 million in 2025, then decreased by 26.93% to $2.3 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $2.3 million in Q2 2026, $1.1 million in Q1 2026, and $3.2 million in Q4 2025.